[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2205771C - Administration amelioree pour traitement de fond - Google Patents

Administration amelioree pour traitement de fond Download PDF

Info

Publication number
CA2205771C
CA2205771C CA002205771A CA2205771A CA2205771C CA 2205771 C CA2205771 C CA 2205771C CA 002205771 A CA002205771 A CA 002205771A CA 2205771 A CA2205771 A CA 2205771A CA 2205771 C CA2205771 C CA 2205771C
Authority
CA
Canada
Prior art keywords
hyaluronan
hbm
amino acids
protein
basic amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002205771A
Other languages
English (en)
Other versions
CA2205771A1 (fr
Inventor
Eva A. Turley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec AG filed Critical Jagotec AG
Priority to CA002205771A priority Critical patent/CA2205771C/fr
Priority to JP54972998A priority patent/JP2001526666A/ja
Priority to AU73286/98A priority patent/AU740631B2/en
Priority to EP98920426A priority patent/EP0998297A2/fr
Priority to PCT/CA1998/000448 priority patent/WO1998052590A2/fr
Priority to NZ501270A priority patent/NZ501270A/en
Publication of CA2205771A1 publication Critical patent/CA2205771A1/fr
Application granted granted Critical
Publication of CA2205771C publication Critical patent/CA2205771C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002205771A 1997-05-22 1997-05-22 Administration amelioree pour traitement de fond Expired - Fee Related CA2205771C (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002205771A CA2205771C (fr) 1997-05-22 1997-05-22 Administration amelioree pour traitement de fond
JP54972998A JP2001526666A (ja) 1997-05-22 1998-05-11 疾患調節薬の放出改良
AU73286/98A AU740631B2 (en) 1997-05-22 1998-05-11 Improved delivery of disease modifiers
EP98920426A EP0998297A2 (fr) 1997-05-22 1998-05-11 Administration amelioree de modificateurs de pathologies
PCT/CA1998/000448 WO1998052590A2 (fr) 1997-05-22 1998-05-11 Administration amelioree de modificateurs de pathologies
NZ501270A NZ501270A (en) 1997-05-22 1998-05-11 Pharmaceutical composition comprising hyaluronan (Mr less than 750,00) and a disease modifier (cytokine, a peptide mimicking a cytokine or a protein mimicking a cytokine) to enhance delivery of disease modifiers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002205771A CA2205771C (fr) 1997-05-22 1997-05-22 Administration amelioree pour traitement de fond

Publications (2)

Publication Number Publication Date
CA2205771A1 CA2205771A1 (fr) 1998-11-22
CA2205771C true CA2205771C (fr) 2002-05-14

Family

ID=4160694

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205771A Expired - Fee Related CA2205771C (fr) 1997-05-22 1997-05-22 Administration amelioree pour traitement de fond

Country Status (6)

Country Link
EP (1) EP0998297A2 (fr)
JP (1) JP2001526666A (fr)
AU (1) AU740631B2 (fr)
CA (1) CA2205771C (fr)
NZ (1) NZ501270A (fr)
WO (1) WO1998052590A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
AU2001250212A1 (en) * 2000-04-20 2001-11-07 Cangene Corporation Rhamm peptide conjugates
WO2004104166A2 (fr) * 2003-05-07 2004-12-02 La Jolla Institute For Molecular Medicine Methodes permettant de faciliter la recuperation de fonctions de cellules souches endogenes, implantees ou transplantees au moyen d'un acide hyaluronique de poids moleculaire eleve
DE202011109558U1 (de) * 2011-12-09 2012-12-12 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die topische Anwendung bei entzündlichen Erkrankungen der Haut und/oder Schleimhaut
FR3002452B1 (fr) * 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
UA125432C2 (uk) 2015-09-23 2022-03-09 Дженентек, Інк. Оптимізовані варіанти анти-vegf антитіл

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
GB9207949D0 (en) * 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
EP0778776A1 (fr) * 1994-08-30 1997-06-18 Hyal Pharmaceutical Corporation Acide hyaluronique et derives destines a la modulation de l'activite cellulaire

Also Published As

Publication number Publication date
NZ501270A (en) 2001-08-31
JP2001526666A (ja) 2001-12-18
EP0998297A2 (fr) 2000-05-10
AU740631B2 (en) 2001-11-08
AU7328698A (en) 1998-12-11
CA2205771A1 (fr) 1998-11-22
WO1998052590A2 (fr) 1998-11-26
WO1998052590A3 (fr) 1999-04-22

Similar Documents

Publication Publication Date Title
US20230279048A1 (en) Compositions containing hc-ha/ptx3 complexes and methods of use thereof
Holmskov et al. Collectins: collagenous C-type lectins of the innate immune defense system
EP0401384B1 (fr) Facteur de stimulation de colonies de granulocytes modifies chimiquement
AU666007B2 (en) Protein formulation comprising growth hormone
JP2752206B2 (ja) 顆粒球コロニー刺激因子を用いる粘膜炎の予防及び治療法
EP1129718A2 (fr) Utilisations thérapeutiques de produits protéiques augmentant le pouvoir bactéricide et/ou la perméabilité
KR20100051695A (ko) 양쪽 친매성 폴리머와 ｂｍｐ 패밀리의 골형성 단백질의 복합체
CA2165727A1 (fr) Matrices de collagene liees par affinite, pour l'administration d'agents biologiquement actifs
CN103140499B (zh) 一种粒细胞集落刺激因子与聚乙二醇的共轭物
US8530417B2 (en) Y-shaped polyethylene glycol modified G-CSF, the preparation and use thereof
CA2205771C (fr) Administration amelioree pour traitement de fond
JP2019523285A (ja) タンパク質およびペプチドの送達のための粒子
Wang et al. Characterization, stability, and formulations of basic fibroblast growth factor
AU2020281098B2 (en) Methods and compositions for treatment of cartilage damage and arthritis
CN1111158A (zh) 含有粒细胞集落刺激因子和肿瘤坏死因子结合蛋白的产物
US20110135624A1 (en) Therapeutic composition for autoimmune conditions
Gottschalk The relation between structure and function in some glycoproteins
US8815812B2 (en) Synthetic arginine substituted peptides and their use
CN101671390A (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
KR930004598B1 (ko) 단백질 수용액
EP0411033B1 (fr) Formulations stables pendant le stockage du m-csf dimerique homogene
JPH08198772A (ja) 顆粒球コロニー刺激因子含有粉末経鼻投与製剤
Carter Glycosylation, intraspecies molecular heterogeneity and trans-species activity of mammalian interferons
EA031390B1 (ru) Система длительного высвобождения гидрофобных белков на основе амида гиалуроновой кислоты
JP2000143694A (ja) 血小板由来白血球貪食能亢進因子の活性化因子

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed